TY - JOUR
AU1 - Sonoda, Tomoaki
AU2 - Umeda, Yukihiro
AU3 - Demura, Yoshiki
AU4 - Tada, Toshihiko
AU5 - Nakashima, Koki
AU6 - Anzai, Masaki
AU7 - Yamaguchi, Makiko
AU8 - Shimada, Akikazu
AU9 - Ohi, Masahiro
AU1 - Honjo, Chisato
AU1 - Waseda, Yuko
AU1 - Akai, Masaya
AU1 - Ishizuka, Tamotsu
AB - INTRODUCTIONGlobally, lung cancer was the leading cause of cancer‐related mortality in 2020, contributing to approximately 1.8 million deaths.1 In recent years, amidst the ongoing development of various drugs, immunotherapy has emerged as a novel treatment option for advanced non‐small cell lung cancer (NSCLC), either alone or in combination with cytotoxic chemotherapy. Furthermore, it has resulted in improved prognosis for patients with advanced NSCLC.2 However, the therapeutic effects after second‐line treatment remain unsatisfactory,3 and further treatment strategies are urgently required.Notably, the results of clinical trials of immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) inhibitors, indicate that they are expected to significantly improve overall survival (OS) despite a lower objective response rate (ORR).4–6 These reproducible results suggest that ICIs have not only direct antitumor effects, but also a positive post‐treatment impact. In fact, several retrospective studies have reported a possible enhancement in the effect of chemotherapy used immediately after ICI administration,7–11 whereas another study has suggested no enhancement.12 All of these reports are retrospective studies and include various anticancer agents, leaving the matter inconclusive.Commonly used anticancer agents for previously treated patients with advanced NSCLC include docetaxel, pemetrexed, gemcitabine, and a combination of 
TI - Efficacy and safety of nanoparticle albumin‐bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non‐small cell lung cancer: A multicenter Phase 2 clinical trial
JF - Cancer Medicine
DO - 10.1002/cam4.5978
DA - 2023-06-01
UR - https://www.deepdyve.com/lp/wiley/efficacy-and-safety-of-nanoparticle-albumin-bound-paclitaxel-WS10hoqL8s
SP - 13041
EP - 13053
VL - 12
IS - 12
DP - DeepDyve
ER -